Description du projet
Une nouvelle technologie pour le développement de probiotiques personnalisés
Les perturbations du microbiome intestinal sont associées à de nombreuses maladies différentes, notamment le diabète, l’obésité et le cancer. Malgré l’importance du microbiome pour la santé, les probiotiques disponibles n’apportent pas assez de bactéries, et dans une variété insuffisante, pour coloniser l’intestin. Pour résoudre ce problème, le projet MBSelect, financé par l’UE, exploitera une technologie récemment développée capable de développer des communautés bactériennes complexes sur des microparticules et de les placer dans des capsules après séchage. Cette technologie permet, pour la première fois, de développer des probiotiques à base de microbiome personnalisés adaptés à n’importe quel objectif, âge ou sexe. Le projet étendra cette technologie innovante au niveau industriel et entreprendra les activités nécessaires à sa commercialisation.
Objectif
Gut-microbiome is an essential part of human health. Gut bacteria imbalance is now recognized as a crucial factor in the development of many diseases – chronic, obesity, diabetes, liver, cardio, cancer and neurodegenerative. Traditional probiotics used today, aimed at restoring this imbalance, are not effective: They are incapable of delivering sufficient number and variety of bacteria to the correct location in the gut and have them colonize. MyBiotics, a microbiome company, developed a novel technology for very efficient growth, delivery, and colonization of needed bacteria types in the gut. The technology uses innovative fermentation methods to grow complex bacteria communities on micro-particles, dry it to powder and place into capsules administered like any probiotic supplement. MyBiotics proved the technology for single-strain-bacteria and for replicating multi-strain biological samples. In this project it is introducing MBSelect, which will remove the reliance on a biological sample and add formulation of multi-strain communities of human bacteria, grown in pre-selected clusters in any combination. The MBSelect innovation enables, for the first time, the creation of personalized, microbiome-based probiotics, fitted to any purpose – recovery from illness, chronic condition, or as supplements – and fitted to specific microbiome needs of different ethnicities, age, and gender. MyBiotics won and executed a Phase1 feasibility study in 2015, which served as a basis for its development since and for this project application. MyBiotics’ objectives in this project are to complete the development of the MBSelect technology, develop its first three probiotic products, scale them to industrial level, test them, and produce the 1st batch for initial commercial market testing immediately following the project; followed by full EU & US commercialization and scaling. The success of MBSelect is key in realizing the potential of MyBiotics and enabling the company to grow.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
7414001 Ness Ziona
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.